Kaida BioPharma, an early-stage pharmaceutical company, announced the launch of its corporate social media channels as it advances novel therapies for gynecological cancers. The company's lead program, KAD101, is set to enter Phase 1 trials in 2025, marking a significant step toward addressing unmet needs in ovarian cancer treatment.
Kaida BioPharma is dedicated to developing targeted anti-cancer hormonal therapies that address the underlying causes of cancers affecting women. Their lead candidate, KAD101, is a novel biologic designed to block the prolactin receptor, thereby preventing cancer cell growth signals and inducing autophagy. The initial focus is on ovarian cancer, a disease with limited effective treatment options for patients with resistance to current therapies.
KAD101: A Novel Approach to Ovarian Cancer Treatment
KAD101 has demonstrated encouraging results in a human clinical study. According to the company, all patients in the study showed tumor reduction with a clean safety profile as a daily injectable. These early findings suggest that KAD101 could offer a new mechanism of action in treating ovarian cancer by targeting the prolactin receptor, a key pathway in cancer cell growth.
Craig Pierson, Founder and Chairman of Kaida BioPharma, emphasized the significant unmet need in ovarian cancer treatment, noting that approximately 90% of patients require more effective options. "Current therapies offer limited efficacy and no durable response. We believe Kaida represents an exciting opportunity to potentially treat the cause and not the problem for ovarian cancer and other high value oncology indications with unmet need including breast cancer and uterine," Pierson stated.
Expanding the Pipeline: KAD102 for Uterine Cancer
In addition to KAD101, Kaida BioPharma is also developing KAD102, an enhanced pure antagonist of KAD101, for the treatment of uterine cancer. This highlights the company's commitment to expanding its portfolio of targeted therapies for gynecological cancers.
Social Media Engagement
The launch of Kaida BioPharma's social media channels on X, LinkedIn, and Facebook aims to enhance communication with the investment, patient, and industry partner communities. This initiative will provide updates on the company's progress and foster engagement with stakeholders.
About Kaida BioPharma
Kaida BioPharma was founded on the research principles and clinical evidence of KAD101 (originally G129R), a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. The company's work is based on collaboration with Dr. John Langenheim, professor at Thomas Jefferson University, and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R.
